Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | CRHBP | P24387 | 1/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.65 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157820 | 0.89 | CRHBP (0.83) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL5181163 | 0.88 | KMT2A (0.76) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL394289 | 0.87 | KCNMA1 (0.79) | KMT2AMEN1KCNMA1ALDH1A1HTT | |
| SCHEMBL4958316 | 0.86 | KCNMA1 (0.64) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL4958325 | 0.86 | KCNMA1 (0.64) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL12230498 | 0.86 | LMNA (0.64) | KMT2AMEN1KCNMA1ALDH1A1LMNA | |
| SCHEMBL1962194 | 0.85 | KCNMA1 (0.75) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL16583563 | 0.84 | TDP1 (0.60) | KMT2AMEN1CRHBPCRHR2KCNMA1 | |
| SCHEMBL7722700 | 0.83 | ALDH1A1 (0.68) | KMT2AMEN1KCNMA1ALDH1A1KDM4E | |
| SCHEMBL28069367 | 0.83 | KCNMA1 (0.78) | KMT2AMEN1KCNMA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104513235-A | Substituted aminopyrimidine compound and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-04-15 | — | — | CN | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8552009-B2 | Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. | 2013-10-08 | — | — | US | disclosed |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7893260-B2 | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100152209-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1954283-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | Hydra Biosciences, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007056124-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | KMT2A 4347/4885MEN1 4683/4885CRHBP 564/4885 |
| US-20100152209-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | KMT2A 4347/4885MEN1 4683/4885CRHBP 564/4885 |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | KMT2A 4347/4885MEN1 4683/4885CRHBP 564/4885 |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | KMT2A 4347/4885MEN1 4683/4885CRHBP 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.